The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYN | -85.93% | -99.89% | -74.34% | -100% |
| S&P | +19.32% | +83.47% | +12.91% | +409% |
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Cell Therapeutics dilutes shareholders while SIGA squashes fears.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$28.00K | 15.2% |
| Market Cap | $3.89M | 108.1% |
| Market Cap / Employee | $176.73K | 0.0% |
| Employees | 22 | 0.0% |
| Net Income | -$4,361.00K | 43.6% |
| EBITDA | -$4,412.00K | 11.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.53M | -54.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.09M | 84.2% |
| Short Term Debt | $675.00K | 11.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -73.83% | -21.3% |
| Return On Invested Capital | -70.37% | -5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,338.00K | -10.9% |
| Operating Free Cash Flow | -$4,319.00K | -10.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.19 | 0.16 | 0.08 | 0.35 | 624.32% |
| Price to Tangible Book Value | 0.77 | 1.79 | -0.47 | -0.41 | -273.34% |
| Enterprise Value to EBITDA | 1.18 | 0.94 | 1.59 | 0.19 | -92.68% |
| Return on Equity | -87.3% | -100.0% | -154.5% | -167.0% | 114.29% |
| Total Debt | $1.57M | $2.86M | $2.89M | $2.76M | 58.83% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
